Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Loss Narrows At MedImmune; Serono's Profits Still Climbing

Oct. 24, 2003

By Aaron Lorenzo

Loss Narrows At MedImmune; Serono's Profits Still Climbing

Oct. 24, 2003

By Aaron Lorenzo

AaiPharma Purchases Four Pain Products From Elan For $100M

Oct. 23, 2003

By Aaron Lorenzo

AaiPharma Purchases Four Pain Products From Elan For $100M

Oct. 23, 2003

By Aaron Lorenzo

Biospect Raises $27M In Series A Round; Diagnostics First Focus

Oct. 22, 2003

By Aaron Lorenzo

Biospect Raises $27M In Series A Round; Diagnostics First Focus

Oct. 22, 2003

By Aaron Lorenzo

Next Up: Renovis Steps Into Growing Biotech IPO Queue

Oct. 21, 2003

By Aaron Lorenzo

Next Up: Renovis Steps Into Growing Biotech IPO Queue

Oct. 21, 2003

By Aaron Lorenzo

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Oct. 20, 2003

By Aaron Lorenzo

Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today)

FDA Signs Off On Namenda For Moderate To Severe Alzheimer's

Oct. 20, 2003

By Aaron Lorenzo

Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today)

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.